https://pharminent.com/amgens-dazodalibep-meets-goals-in-phase-3-sjogrens-trial/ 2026-09-23T12:13:20Z Pharminent en Amgen's dazodalibep meets goals in phase 3 Sjögren's trial 2026-09-23T11:55:19Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-september-22-2026/ 2026-09-22T21:21:58Z Pharminent en Oncology Intelligence Digest • September 22, 2026 2026-09-22T21:13:18Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-22-2026/ 2026-09-22T14:57:05Z Pharminent en Strategic News Watch • September 22, 2026 2026-09-22T14:57:05Z Blog https://pharminent.com/fda-approves-lillys-breast-cancer-combination-treatment/ 2026-09-22T12:27:54Z Pharminent en FDA approves Lilly's breast cancer combination treatment 2026-09-22T12:27:49Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-september-21-2026/ 2026-09-22T11:59:47Z Pharminent en Rare Disease & Gene Therapy Digest • September 21, 2026 2026-09-22T11:59:45Z Blog https://pharminent.com/telix-to-acquire-itm-in-deal-worth-up-to-2-35b/ 2026-09-21T13:18:15Z Pharminent en Telix to acquire ITM in deal worth up to $2.35B 2026-09-21T13:05:02Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-september-21-2026/ 2026-09-21T16:54:31Z Pharminent en Strategic News Watch • September 21, 2026 2026-09-21T16:54:31Z Blog